Adenocarcinoma of the Esophagus Completed Phase 2 Trials for Pralatrexate (DB06813)

IndicationStatusPhase
DBCOND0030040 (Adenocarcinoma of the Esophagus)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01129206Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based TherapyTreatment